News >

Building On Immunotherapy, Preventing Acquired Resistance Are Next Steps in Lung Cancer Research

Ellie Leick
Published: Friday, Mar 20, 2020

David P. Carbone, MD, PhD, director of the Thoracic Oncology Center at The Ohio State University Comprehensive Cancer Center James

David P. Carbone, MD, PhD

Checkpoint inhibitors and next-generation TKIs have demonstrated improved survival outcomes in patients with non–small cell lung cancer (NSCLC); however, ongoing research efforts are looking to build upon the benefits with combination strategies and prevent acquired resistance to treatment, explained David P. Carbone, MD, PhD.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication